Plus Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Plus Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Plus Therapeutics Inc Strategy Report
- Understand Plus Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Plus Therapeutics Inc (Plus Therapeutics), formerly Cytori Therapeutics Inc is a developmental-stage pharmaceutical company, which focuses on the discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. The company’s pipeline of candidate drug products includes Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel; Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin; BMEDA-chelated rhenium nanoliposome (RNL); and a co-encapsulated, doxorubicin and rhenium nanoliposome (DRNL). It uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Irvine, Texas, the US.
Plus Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Doceplus- Relapsed Small Cell Lung Cancer |
RNL- Recurrent Glioblastoma, Ovarian Carcinomatosis, Leptomeningeal Carcinomatosis, Breast Cancer, and Cancers of Head, Neck and Liver |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In December, the company entered into an agreement with K2bio for the creation of novel diagnostics for tumor cell and molecular biomarker studies in cerebrospinal fluid (csf). |
2023 | Contracts/Agreements | In September, the company entered into an agreement with Biocept to exclusively license Biocept's CNSide, a CSF-based tumor cell capture and enumeration platform, for patients receiving CNS radiotherapy. |
2023 | Contracts/Agreements | In May, the company and Piramal Pharma Solutions expanded their partnership to produce additional cGMP liposome intermediate drug products. |
Competitor Comparison
Key Parameters | Plus Therapeutics Inc | Bayer AG | Alaunos Therapeutics Inc | VBI Vaccines Inc | MediciNova Inc |
---|---|---|---|---|---|
Headquarters | United States of America | Germany | United States of America | United States of America | United States of America |
City | Austin | Leverkusen | Houston | Cambridge | La Jolla |
State/Province | Texas | Nordrhein-Westfalen | Texas | Massachusetts | California |
No. of Employees | 20 | 99,723 | 34 | 190 | 13 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Richard J. Hawkins | Chairman | Executive Board | 2018 | 75 |
Marc H. Hedrick, M.D. | Director; Chief Executive Officer; President | Executive Board | 2014 | 60 |
Andrew Sims | Chief Financial Officer; Vice President | Senior Management | 2020 | 50 |
Norman LaFrance | Chief Medical Officer; Senior Vice President | Senior Management | 2021 | 75 |
Russ Havranek | Vice President - Corporate Strategy and New Product Planning | Senior Management | 2014 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward